Rhumbline Advisers reduced its holdings in National Research Corporation (NASDAQ:NRCIA) by 6.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,467 shares of the business services provider’s stock after selling 697 shares during the quarter. Rhumbline Advisers’ holdings in National Research Corporation were worth $282,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Rice Hall James & Associates LLC increased its holdings in shares of National Research Corporation by 1.0% in the second quarter. Rice Hall James & Associates LLC now owns 15,035 shares of the business services provider’s stock worth $404,000 after acquiring an additional 155 shares in the last quarter. Algert Global LLC bought a new stake in shares of National Research Corporation in the second quarter worth about $384,000. Schwab Charles Investment Management Inc. increased its holdings in shares of National Research Corporation by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 30,453 shares of the business services provider’s stock worth $820,000 after acquiring an additional 190 shares in the last quarter. Finally, Strs Ohio increased its holdings in shares of National Research Corporation by 210.3% in the second quarter. Strs Ohio now owns 12,100 shares of the business services provider’s stock worth $325,000 after acquiring an additional 8,200 shares in the last quarter. Institutional investors own 28.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/10/12/national-research-corporation-nrcia-holdings-lessened-by-rhumbline-advisers.html.
National Research Corporation (NASDAQ NRCIA) opened at 37.15 on Thursday. National Research Corporation has a 12-month low of $14.35 and a 12-month high of $41.99. The company’s 50 day moving average price is $35.15 and its 200-day moving average price is $28.20. The company has a market capitalization of $902.71 million, a P/E ratio of 40.91 and a beta of 1.72.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 29th will be paid a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date is Thursday, September 28th. National Research Corporation’s dividend payout ratio is 76.92%.
Separately, Zacks Investment Research downgraded National Research Corporation from a “buy” rating to a “hold” rating in a report on Saturday, August 12th.
National Research Corporation Profile
National Research Corporation provides analytics and insights for the patient and employee experience in serving the healthcare providers, payers, and other healthcare organizations in the United States and Canada. Its portfolio of subscription-based solutions offer information and analysis services in a range of elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.
What are top analysts saying about National Research Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for National Research Corporation and related companies.